title: Signatures of drug sensitivity in nonsmall cell lung cancer.
abstract: We profiled receptor tyrosine kinase pathway activation and key gene mutations in eight human lung tumor cell lines and 50 human lung tumor tissue samples to define molecular pathways. A panel of eight kinase inhibitors was used to determine whether blocking pathway activation affected the tumor cell growth. The HER1 pathway in HER1 mutant cell lines HCC827 and H1975 were found to be highly activated and sensitive to HER1 inhibition. H1993 is a c-MET amplified cell line showing c-MET and HER1 pathway activation and responsiveness to c-MET inhibitor treatment. IGF-1R pathway activated H358 and A549 cells are sensitive to IGF-1R inhibition. The downstream PI3K inhibitor, BEZ-235, effectively inhibited tumor cell growth in most of the cell lines tested, except the H1993 and H1650 cells, while the MEK inhibitor PD-325901 was effective in blocking the growth of KRAS mutated cell line H1734 but not H358, A549 and H460. Hierarchical clustering of primary tumor samples with the corresponding tumor cell lines based on their pathway signatures revealed similar profiles for HER1, c-MET and IGF-1R pathway activation and predict potential treatment options for the primary tumors based on the tumor cell lines response to the panel of kinase inhibitors.
authors.affiliation: Department of Research and Development, Prometheus Inc. 9410, Carroll Park Drive, San Diego, CA 92121, USA.
authors.forename: Hua C
authors.initials: HC
authors.lastname: Gong
authors.forename: Sean
authors.initials: S
authors.lastname: Wang
authors.forename: Gary
authors.initials: G
authors.lastname: Mayer
authors.forename: Guoan
authors.initials: G
authors.lastname: Chen
authors.forename: Glen
authors.initials: G
authors.lastname: Leesman
authors.forename: Sharat
authors.initials: S
authors.lastname: Singh
authors.forename: David G
authors.initials: DG
authors.lastname: Beer
references.citation: Oncologist. 2006 Jun;11(6):655-65
references.pmid: 16794244
references.citation: Mol Pharmacol. 2007 Nov;72(5):1171-80
references.pmid: 17702889
references.citation: Cancer Res. 2005 Jun 15;65(12):5076-83
references.pmid: 15958551
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
references.pmid: 15329413
references.citation: Cell Prolif. 2007 Aug;40(4):580-94
references.pmid: 17635524
references.citation: BioDrugs. 2009;23(6):377-89
references.pmid: 19894779
references.citation: Nat Med. 2006 Nov;12(11):1294-300
references.pmid: 17057710
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92
references.pmid: 2738938
references.citation: Cancer Res. 1999 Dec 15;59(24):6239-45
references.pmid: 10626818
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3651-6
references.pmid: 18559577
references.citation: Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70
references.pmid: 15897464
references.citation: Science. 2006 Oct 13;314(5797):268-74
references.pmid: 16959974
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Oncogene. 2011 Jun 2;30(22):2547-57
references.pmid: 21278786
references.citation: PLoS Med. 2005 Jan;2(1):e17
references.pmid: 15696205
references.citation: Oncologist. 2005 Aug;10(7):467-70
references.pmid: 16079313
references.citation: N Engl J Med. 2005 Feb 24;352(8):786-92
references.pmid: 15728811
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41
references.pmid: 18077425
references.citation: Curr Treat Options Oncol. 2010 Jun;11(1-2):36-44
references.pmid: 20676809
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Hum Pathol. 1985 Jun;16(6):569-79
references.pmid: 2987102
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014